Kawasumi Laboratories, Incorporated, commonly referred to as Kawasumi, is a leading player in the medical device industry, headquartered in Japan. Established in 1950, the company has made significant strides in the development of innovative healthcare solutions, particularly in the fields of dialysis and blood purification. With a strong presence in Asia and expanding operations globally, Kawasumi is renowned for its high-quality products, including dialysis filters and blood bags, which are distinguished by their advanced technology and reliability. The company has achieved notable milestones, solidifying its market position as a trusted provider of medical devices. Kawasumi's commitment to research and development ensures that it remains at the forefront of the industry, continually enhancing patient care through its unique offerings.
How does Kawasumi Laboratories, Incorporated's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Kawasumi Laboratories, Incorporated's score of 48 is higher than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Kawasumi Laboratories, Incorporated, headquartered in Japan (JP), currently does not report specific carbon emissions data for the most recent year. As a current subsidiary of Sumitomo Bakelite Company Limited, any climate commitments or emissions data may be inherited from this parent organisation. Kawasumi Laboratories has not outlined specific reduction targets or initiatives in its own right. However, it is important to note that the climate commitments and performance metrics may be influenced by the sustainability strategies of Sumitomo Bakelite Company Limited, from which Kawasumi Laboratories cascades its data. As of now, there are no documented emissions figures, reduction targets, or climate pledges directly associated with Kawasumi Laboratories. The company may align with broader industry standards and practices as part of its corporate family relationship, but specific details remain unspecified.
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 90,643,000 | 00,000,000 | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 145,869,000 | 000,000,000 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 |
Kawasumi Laboratories, Incorporated's Scope 3 emissions, which decreased by 79% last year and decreased by approximately 80% since 2021, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 76% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Kawasumi Laboratories, Incorporated has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.